{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:29:13Z","timestamp":1790206153328,"version":"4.1.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8,15]]},"DOI":"10.1097\/qai.0b013e3181142d26","type":"journal-article","created":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T04:04:07Z","timestamp":1182485047000},"page":"508-514","source":"Crossref","is-referenced-by-count":56,"title":["Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual Nucleosides"],"prefix":"10.1097","volume":"45","author":[{"given":"Michael P","family":"Dub\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Komarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K","family":"Grinspoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory K","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronenn","family":"Roubenoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Tebas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210131","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults.","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-4-20210131","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1468-1293.2003.00159.x","article-title":"HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.","volume":"4","author":"Miller","year":"2003","journal-title":"HIV Med"},{"key":"R3-4-20210131","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000182230.47819.aa","article-title":"Fat distribution in men with HIV infection.","volume":"40","author":"Bacchetti","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-4-20210131","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","article-title":"Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.","volume":"19","author":"Dube","year":"2005","journal-title":"AIDS"},{"key":"R5-4-20210131","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","article-title":"Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.","volume":"14","author":"Mallal","year":"2000","journal-title":"AIDS"},{"key":"R6-4-20210131","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","article-title":"Clinical assessment of HIV-associated lipodystrophy in an ambulatory population.","volume":"15","author":"Lichtenstein","year":"2001","journal-title":"AIDS"},{"key":"R7-4-20210131","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-200212060-00010","article-title":"Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.","volume":"16","author":"Joly","year":"2002","journal-title":"AIDS"},{"key":"R8-4-20210131","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R9-4-20210131","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.qai.0000167478.28051.3a","article-title":"Redefining lipodystrophy syndrome: risks and impact on clinical decision making.","volume":"39","author":"Lichtenstein","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-4-20210131","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.","volume":"17","author":"Mallon","year":"2003","journal-title":"AIDS"},{"key":"R11-4-20210131","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men.","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"R12-4-20210131","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa030264","article-title":"Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.","volume":"349","author":"Robbins","year":"2003","journal-title":"N Engl J Med"},{"key":"R13-4-20210131","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa030265","article-title":"Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.","volume":"349","author":"Shafer","year":"2003","journal-title":"N Engl J Med"},{"key":"R16-4-20210131","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-200708150-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:47:36Z","timestamp":1786034856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-200708150-00004"}},"subtitle":["Dual X-Ray Absorptiometry Results From A5005s, a Substudy of Adult Clinical Trials Group 384"],"short-title":[],"issued":{"date-parts":[[2007,8,15]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181142d26","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8,15]]}}}